|
1
|
Nam S, Chung JW and Yang JY: WNT5A
correlates with clinicopathological characteristics in gastric
cancer: A meta-analysis. Cell Physiol Biochem. 41:33–40. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. 3:CD0040642010.
|
|
3
|
Zou K, Yang S, Zheng L, Yang C and Xiong
B: Efficacy and safety of target combined chemotherapy in advanced
gastric cancer: A meta-analysis and system review. BMC Cancer.
16:7372016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duo-Ji MM, Ci-Ren BS, Long ZW, Zhang XH
and Luo DL: Short-term efficacy of different chemotherapy regimens
in the treatment of advanced gastric cancer: A network
meta-analysis. Oncotarget. 8:37896–37911. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
De Vita F, Orditura M, Matano E, Bianco R,
Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto
E, et al: A phase II study of biweekly oxaliplatin plus infusional
5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment
of advanced gastric cancer patients. Br J Cancer. 92:1644–1649.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chao Y, Yeh KH, Chang CJ, Chen LT, Chao
TY, Wu MF, Chang CS, Chang JY, Chung CY, Kao WY, et al: Phase II
study of weekly oxaliplatin and 24-h infusion of high-dose
5-fluorouracil and folinic acid in the treatment of advanced
gastric cancer. Br J Cancer. 91:453–458. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Santini D, Graziano F, Catalano V, Di Seri
M, Testa E, Baldelli AM, Giordani P, La Cesa A, Spalletta B,
Vincenzi B, et al: Weekly oxaliplatin, 5-fluorouracil and folinic
acid (OXALF) as first-line chemotherapy for elderly patients with
advanced gastric cancer: Results of a phase II trial. BMC Cancer.
6:1252006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu F, Zhang HG, Ran FW, Zhang XR and Shi
YK: FOLFOX4 regimen versus DP(O)F regimen for advanced gastric
cancer. Ai Zheng. 27:413–417. 2008.(In Chinese). PubMed/NCBI
|
|
9
|
Fayette J, Fontaine-Delaruelle C, Ambrun
A, Daveau C, Poupart M, Ramade A, Zrounba P, Neidhardt EM, Péron J,
Diallo A, et al: Neoadjuvant modified TPF (docetaxel, cisplatin,
fluorouracil) for patients unfit to standard TPF in locally
advanced head and neck squamous cell carcinoma: A study of 48
patients. Oncotarget. 7:37297–37304. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawada J, Nishino M, Hosoda Y, Hoshino H,
Okano M, Nagai K, Okuyama M, Kim Y and Tsujinaka T: Analysis of
5-fluorouracil and leucovorin combined with weekly paclitaxel in
advanced gastric cancer. Gan To Kagaku Ryoho. 43:1951–1953.
2016.(In Japanese). PubMed/NCBI
|
|
11
|
Kaasa T and Wessel J: The Edmonton
functional assessment tool: Further development and validation for
use in palliative care. J Palliat Care. 17:5–11. 2001.PubMed/NCBI
|
|
12
|
Ji L, Gu D, Tan X, Sun H and Chen J: A
meta-analysis of clinical trials over regimens with or without
cetuximab for advanced gastric cancer patients. J BUON. 22:900–904.
2017.PubMed/NCBI
|
|
13
|
Li R, Yu J and Wang C: Silibinin promotes
the apoptosis of gastric cancer BGC823 cells through caspase
pathway. J BUON. 22:1148–1153. 2017.PubMed/NCBI
|
|
14
|
Hofheinz R, Clouth J, Borchardt-Wagner J,
Wagner U, Weidling E, Jen MH and Brück P: Patient preferences for
palliative treatment of locally advanced or metastatic gastric
cancer and adenocarcinoma of the gastroesophageal junction: A
choice-based conjoint analysis study from Germany. BMC Cancer.
16:9372016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lordick F and Terashima M: Gastric cancer
adjuvant therapy. Best Pract Res Clin Gastroenterol. 30:581–591.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song H, Zhu J and Lu D: Molecular-targeted
first-line therapy for advanced gastric cancer. Cochrane Database
Syst Rev. 7:CD0114612016.PubMed/NCBI
|
|
17
|
Elimova E and Ajani JA: Surgical resection
first for localized gastric adenocarcinoma: Are there adjuvant
options? J Clin Oncol. 33:3085–3091. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim JY, Ryoo HM, Bae SH, Kang BW, Chae YS,
Yoon S, Baek JH, Kim MK, Lee KH, Lee SA, et al: Multi-center
randomized phase II study of weekly docetaxel versus weekly
docetaxel-plus-oxaliplatin as a second-line chemotherapy for
patients with advanced gastric cancer. Anticancer Res.
35:3531–3536. 2015.PubMed/NCBI
|
|
19
|
Yoshino S, Furuya T, Shimizu R, Ozasa H,
Nishimura T, Fukuda S, Kawaoka T, Hazama S and Oka M: Combination
phase II study of weekly paclitaxel and 5′-DFUR for unresectable or
recurrent gastric cancer. Anticancer Res. 33:2629–2633.
2013.PubMed/NCBI
|
|
20
|
Wang X, Wang Y, Qiu M, Li Q, Li ZP, He B,
Xu F, Shen YL, Gou HF, Yang Y, et al: Postoperative
chemoradiotherapy in gastric cancer: A phase I study of
radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil,
and leucovorin (FOLFOX regimen). Med Oncol. 28 Suppl 1:S274–S279.
2011. View Article : Google Scholar : PubMed/NCBI
|
